CYTO Altamira Therapeutics
- 1.5600
- +0.0300+1.96%
- 1.5200
- -0.0400-2.56%
Altamira Therapeutics News
Altamira Therapeutics Announces Publication of Positive Results From Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Investor Conference on April 18, 2024. The
Altamira Therapeutics Announces 2024 Annual Meeting
Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Altamira Therapeutics Ltd.
Altamira Therapeutics FY EPS $(16.47) Sales $284.47K Down From $330.37K YoY
Altamira Therapeutics (NASDAQ:CYTO) reported quarterly losses of $(16.47) per share. This is a 97.38 percent increase over losses of $(629.80) per share from the same period last year. The company re
Altamira Therapeutics (CYTO.US): The 2023 FY financial report achieved revenue of US$284.47 million, previous value of US$3303.7 million; earnings per share were -16.47 dollars, previous value of -629.80 dollars.
Altamira Therapeutics (CYTO.US): The 2023 FY financial report achieved revenue of US$284.47 million, previous value of US$3303.7 million; earnings per share were -16.47 dollars, previous value of -629.80 dollars.
Altamira Therapeutics FY GAAP EPS CHF(14.80) Up From CHF(409.60) YoY, Other Operating Income CHF255.59K Up From CHF9.33K YoY
Altamira Therapeutics FY GAAP EPS CHF(14.80) Up From CHF(409.60) YoY, Other Operating Income CHF255.59K Up From CHF9.33K YoY
Altamira Therapeutics 2023 Loss/Shr CHF7.88 >CYTO
Altamira Therapeutics 2023 Loss/Shr CHF7.88 >CYTO
Earnings Scheduled For April 10, 2024
Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion. • Altamira Therapeutics (NASDAQ:CYTO) is est
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA del
Sector Update: Health Care Stocks Softer in Afternoon Trading
Health care stocks were easing Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.2%. The iShares Biotechnology ETF (IBB) decreas
12 Health Care Stocks Moving In Monday's Intraday Session
GainersLandos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The market value of their outstanding shares is at $66.8 million. The company's, Q4 earnings came ou
Altamira, Univercells Partner to Test MRNA Vaccine Delivery
Altamira Therapeutics (CYTO) said Monday it is collaborating with Univercells Group to assess SemaPhore platform for mRNA vaccine delivery.
Altamira Stock Rallies 44% on Univercells MRNA Collaboration
Crude Oil Moves Higher; US New Home Sales Fall In February
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S
Why Altamira Therapeutics Stock Is Racing Higher
Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares are trading higher Monday after the company announced that it has entered into a collaboration agreement with Univercells Group to evaluate the use of t
Nkarta, Nuvation Bio, Canopy Growth Among Healthcare Movers
US Stocks Down; Chicago Fed National Activity Index Rises In February
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell
Altamira Therapeutics Announces Collaboration With Univercells Group on Nanoparticle-Delivered MRNA Vaccines
HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Univercells to test proprietary mRNA vaccine delivered with Altamira's SemaPhore nanoparticlesTargeting safer and accessible mRNA vaccinesAltami
Vivani Medical, Altamira Therapeutics, Quoin Pharmaceuticals Among Healthcare Movers
Analysis
Price Target
No Data
